Bristol Myers Squibb’s deucravacitinib meets co-primary endpoints in psoriasis study #BMS #psoriasis #bmsemployee “Deucravacitinib, a novel, oral and selective tyrosine kinase 2 (TYK2) inhibitor, is being assessed in clinical studies across multiple immune-mediated diseases such as psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. The phase 3 POETYK PSO-1 trial assessed 6mg of deucravacitinib once daily. It met both co-primary endpoints versus placebo in the trial. The study also achieved multiple major secondary endpoints, including demonstrating deucravacitinib was superior to Otezla (apremilast). POETYK PSO-1 is said to be the first of two global phase 3 studies designed to assess the safety and efficacy of deucravacitinib compared to placebo and Otezla in patients with moderate to severe plaque psoriasis.” #medicalaffairs #medicalscienceliaison https://www.instagram.com/p/CHR3KWRDiD1/?igshid=1nphelc5ghttr